BioStem Technologies, Inc.
BSEM
Get informed when a big investor buys or sells
+ FollowMarket Cap$41.95M
Close$
Share Statistics
| Market cap | $41.95 Million |
|---|---|
| Enterprise Value | $36.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 0.26 |
| Outstanding Shares | 17,327,652 |
Return
| Return on Equity | -102.45% |
|---|---|
| Return on Assets | -57.95% |
| Return on Invested Capital | -84.50% |
Valuation & Multiples
| P/E Ratio | -1.48 |
|---|---|
| PEG | -0.1 |
| Price to Sales | -0.56 |
| Price to Book Ratio | 2.25 |
| Enterprise Value to Revenue | -0.6 |
| Enterprise Value to EBIT | -1.55 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$6.35 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$7.17 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioStem Technologies, Inc.
73 employees
CEO: Jason Matuszewski BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue a...